CORC

在结果中检索

CORC

浏览/检索结果: 共30条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
The Role of Anti-EGFR Monoclonal Antibody in mCRC Maintenance Therapy 期刊论文
FRONTIERS IN MOLECULAR BIOSCIENCES, 2022, 卷号: 9
作者:  Yuan, Meiqin;  Wang, Zeng;  Lv, Wangxia;  Pan, Hongming
收藏  |  浏览/下载：17/0  |  提交时间：2022/05/16
Intraoperative molecular imaging clinical trials: a review of 2020 conference proceedings 期刊论文
JOURNAL OF BIOMEDICAL OPTICS, 2021, 卷号: 26, 期号: 5, 页码: 22
作者:  Azari, Feredun;  Kennedy, Gregory;  Bernstein, Elizabeth;  Hadjipanayis, Constantinos;  Vahrmeijer, Alexander L.
收藏  |  浏览/下载：22/0  |  提交时间：2021/08/15
Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT 期刊论文
Journal of Clinical Oncology, 2016, 卷号: 34
作者:  Peeters M., Kim T.W., Li J., Cascinu S., Ruff P., Suresh A.V., Thomas A., Tjulandin S., Guan X., Hoang T., Hei Y.J., Price T.J.
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT. 会议论文
作者:  Peeters, Marc;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano;  Ruff, Paul
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05
Efficacy of panitumumab vs cetuximab in patients with wildtype KRAS exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT 期刊论文
Journal of Clinical Oncology, 2016
作者:  Peeters M., Kim T.W., Li J., Cascinu S., Ruff P., Suresh A.V., Thomas A., Tjulandin S., Guan X., Price T.J.
收藏  |  浏览/下载：8/0  |  提交时间：2019/12/05
Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumab 期刊论文
ONCOTARGET, 2016
Wang, Aidong; Cui, Ming; Qu, Hong; Di, Jiabo; Wang, Zaozao; Xing, Jiadi; Wu, Fan; Wu, Wei; Wang, Xicheng; Shen, Lin; Jiang, Beihai; Su, Xiangqian
收藏  |  浏览/下载：8/0  |  提交时间：2017/12/04
Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer 期刊论文
EUROPEAN JOURNAL OF CANCER, 2016, 卷号: 68
作者:  Price, Timothy;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano;  Ruff, Paul
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/06
Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials 期刊论文
TUMOR BIOLOGY, 2015, 卷号: 36, 期号: 5
作者:  Wang, Qiaoli;  Qi, Yuexiao;  Zhang, Di;  Gong, Caifeng;  Yao, Anqi
收藏  |  浏览/下载：4/0  |  提交时间：2019/12/05
Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). 会议论文
作者:  Price, Timothy Jay;  Newhall, Kathryn;  Peeters, Marc;  Kim, Tae Won;  Li, Jin
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/13
Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT 会议论文
作者:  Peeters, Marc;  Price, Timothy Jay;  Kim, Tae Won;  Li, Jin;  Cascinu, Stefano
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/13

©版权所有 ©2017 CSpace - Powered by CSpace